- Home
- AEE vs UTHR Comparison
AEE vs UTHR Comparison
Compare AEE & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEE
- UTHR
- Stock Information
- Founded
- AEE 1901
- UTHR 1996
- Country
- AEE United States
- UTHR United States
- Employees
- AEE N/A
- UTHR N/A
- Industry
- AEE Power Generation
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- AEE Utilities
- UTHR Health Care
- Exchange
- AEE Nasdaq
- UTHR Nasdaq
- Market Cap
- AEE 27.3B
- UTHR 20.3B
- IPO Year
- AEE N/A
- UTHR 1999
- Fundamental
- Price
- AEE $104.77
- UTHR $475.02
- Analyst Decision
- AEE Buy
- UTHR Buy
- Analyst Count
- AEE 12
- UTHR 12
- Target Price
- AEE $109.83
- UTHR $495.08
- AVG Volume (30 Days)
- AEE 1.6M
- UTHR 560.7K
- Earning Date
- AEE 11-05-2025
- UTHR 10-29-2025
- Dividend Yield
- AEE 2.75%
- UTHR N/A
- EPS Growth
- AEE 22.35
- UTHR 16.08
- EPS
- AEE 5.21
- UTHR 26.38
- Revenue
- AEE $8,635,000,000.00
- UTHR $3,128,400,000.00
- Revenue This Year
- AEE $13.31
- UTHR $13.68
- Revenue Next Year
- AEE $5.95
- UTHR $5.63
- P/E Ratio
- AEE $19.87
- UTHR $18.00
- Revenue Growth
- AEE 23.25
- UTHR 13.50
- 52 Week Low
- AEE $86.40
- UTHR $266.98
- 52 Week High
- AEE $106.73
- UTHR $485.32
- Technical
- Relative Strength Index (RSI)
- AEE 54.30
- UTHR 68.73
- Support Level
- AEE $102.82
- UTHR $444.04
- Resistance Level
- AEE $106.08
- UTHR $482.31
- Average True Range (ATR)
- AEE 1.56
- UTHR 11.75
- MACD
- AEE -0.02
- UTHR 1.36
- Stochastic Oscillator
- AEE 74.84
- UTHR 80.80
About AEE Ameren Corporation
Ameren owns rate-regulated generation, transmission, and distribution networks that deliver electricity and natural gas through the company's two main subsidiaries, Ameren Missouri and Ameren Illinois. It serves 2.5 million electricity customers and approximately 1 million natural gas customers accross its two service territories.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.